Bausch Health Cos (NYSE:BHC) Sees Strong Trading Volume After Earnings Beat

Bausch Health Cos Inc. (NYSE:BHC) shares saw strong trading volume on Thursday after the company announced better than expected quarterly earnings. Approximately 3,494,455 shares were traded during mid-day trading, an increase of 66% from the previous session’s volume of 2,104,088 shares.The stock last traded at $5.8570 and had previously closed at $4.68.

The company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.30. Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.The firm had revenue of $2.83 billion during the quarter, compared to analysts’ expectations of $2.59 billion.

Bausch Health Cos News Summary

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Revenue and earnings beat expectations: Second-quarter revenue was approximately $2.85 billion, up 13% year over year, while adjusted earnings per share rose 40% to $1.26, exceeding the $0.96 consensus estimate. GAAP earnings per share increased to $0.68 from $0.40. Bausch Health Announces Second Quarter 2026 Results, Raises Guidance
• Positive Sentiment: Profitability and cash flow improved: Adjusted EBITDA attributable to Bausch Health reached $1.075 billion, up 28%, while operating cash flow was $517 million and adjusted cash flow from operations was $471 million. Bausch Health excluding Bausch + Lomb recorded its thirteenth consecutive quarter of year-over-year revenue growth. Bausch Health Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Full-year guidance was raised: Management increased 2026 revenue guidance to $10.8 billion-$11.0 billion, above the roughly $10.7 billion analyst consensus, and also raised its adjusted EBITDA and adjusted operating cash-flow outlook. Bausch Health Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Analysts are reviewing the underlying metrics: Zacks noted that revenue and EPS were strong, but investors will also be watching segment trends and other operating indicators to determine how sustainable the beat is. Bausch Reports Q2 Earnings: Key Metrics
• Negative Sentiment: Forward earnings expectations may soften: Zacks Research expects weaker earnings for BHC, which could limit the benefit of the quarterly beat if analysts reduce future estimates. Zacks Research Expects Weaker Earnings for Bausch Health
• Negative Sentiment: Balance-sheet risk remains significant: BHC continues to carry substantial leverage, with a debt-to-equity ratio above 50, while its net margin remains negative. The stock also remains below its 50-day and 200-day moving averages, indicating that investors may require continued execution before sentiment improves.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BHC. Zacks Research cut shares of Bausch Health Cos from a “hold” rating to a “strong sell” rating in a report on Friday, July 24th. Weiss Ratings lowered shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th. Royal Bank Of Canada decreased their target price on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research report on Monday, April 27th. Finally, Jefferies Financial Group upgraded shares of Bausch Health Cos to a “hold” rating in a research note on Wednesday, July 22nd. Five equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $8.00.

Insider Activity

In related news, Director Frank D. Lee sold 24,456 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total value of $132,796.08. Following the completion of the transaction, the director directly owned 49,339 shares of the company’s stock, valued at $267,910.77. This trade represents a 33.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Bausch Health Cos during the first quarter worth $68,000. Jones Financial Companies Lllp increased its position in shares of Bausch Health Cos by 1,548.9% in the 1st quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock valued at $162,000 after acquiring an additional 23,451 shares during the period. Goldman Sachs Group Inc. raised its stake in Bausch Health Cos by 97.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock worth $6,136,000 after acquiring an additional 467,270 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Bausch Health Cos by 3.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock worth $2,102,000 after acquiring an additional 9,834 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Bausch Health Cos by 11.2% during the 2nd quarter. Geode Capital Management LLC now owns 840,418 shares of the company’s stock worth $5,597,000 after acquiring an additional 84,892 shares during the period. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Cos Trading Up 26.5%

The company has a current ratio of 1.32, a quick ratio of 0.97 and a debt-to-equity ratio of 54.68. The stock has a 50-day simple moving average of $4.95 and a 200 day simple moving average of $5.47. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -1.83 and a beta of 0.42.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.